Medical Communications

Showing 15 posts of 6127 posts found.

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023 Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023 Medical Communications European Commission, Oncology, Orserdu, breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023 Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023 Medical Communications Dermatology, EC, Litfulo, alopecia

Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent …

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

September 18, 2023 Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …

GSK and Save the Children extend partnership for unvaccinated children

September 15, 2023 Medical Communications GSK, Immunology, childhood vaccination, vaccines

GSK and Save the Children have announced that they will be renewing their partnership for an additional five years. GSK …

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

September 14, 2023 Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …

FDA approves LimFlow system for patients with CLTI

September 13, 2023 Medical Communications CLTI, Devices, FDA, LimFlow

LimFlow SA has announced that the US Food and Drug Administration (FDA) has approved its LimFlow System for the treatment …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023 Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023 Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

September 4, 2023 Medical Communications AstraZeneca, CLL, China, Oncology, SLL

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …

Novo Nordisk launches Wegovy in the UK

September 4, 2023 Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …

FDA approves new ADHD and BED generics

September 1, 2023 Medical Communications BED, FDA, Pharmacy, generic medicines

The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine …

First patient dosed in phase 1 study for chronic hepatitis B treatment

August 31, 2023 Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …

FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS

August 25, 2023 Medical Communications FDA, MS, Neurology, Sandoz

Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …

Latest content